Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Press Release : T-knife Therapeutics Announces the Appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer

04/07/2021 | 06:00am EDT
 
   San Francisco, CA / Berlin, Germany -- April 7, 2021 -- T-knife 
Therapeutics, Inc., a next-generation T-cell receptor company developing 
innovative therapeutics for the benefit of solid tumor patients and 
their families, today announced the appointment of Donald Wuchterl as 
Senior Vice President and Chief Manufacturing Officer. In this newly 
appointed role, Mr. Wuchterl will oversee process and analytical 
development, quality assurance and quality control, and viral vector and 
cell therapy manufacturing activities. 
 
   "I am very pleased to welcome Don to the T-knife team," stated Thomas M. 
Soloway, Chief Executive Officer of T-knife. "Don's proven track-record 
of building and leading highly functioning cell therapy, biologics and 
gene therapy manufacturing organizations will be a significant asset to 
our platform and development programs. We look forward to the 
contributions Don will make as we advance our lead program targeting 
MAGE-A1 into the clinic later this year and continue to build a leading 
pipeline of innovative TCR-T product candidates." 
 
   "I am honored to join the T-knife executive team at this important 
inflection point in the company's development," said Mr. Wuchterl. 
"T-knife has established itself as an emerging leader in the field of 
TCR-T cell therapy and is well positioned for meaningful near-term 
catalysts. I look forward to working with the T-knife team to deliver on 
the promise of its HuTCR platform to provide transformative benefits for 
solid tumor cancer patients." 
 
   Mr. Wuchterl brings over 29 years of experience in the life sciences 
industries, with senior roles in operations and CMC. He has significant 
experience building and leading cGMP organizations and facilities. He 
joins T-knife from Audentes Therapeutics (an Astellas Company), a gene 
therapy company focused on developing and commercializing innovative 
products for patients living with serious, life-threatening rare 
neuromuscular diseases, where he most recently served as Senior Vice 
President, Technical Operations & Quality. Prior to Audentes, Mr. 
Wuchterl served as Senior Vice President and Chief Operating Officer at 
Cytovance Biologics, a leading biopharmaceutical contract manufacturing 
company. Prior to Cytovance, Mr. Wuchterl held positions of increasing 
responsibility with Dendreon, Shire HGT, Amgen, Biogen Idec and Roche. 
Mr. Wuchterl has a B.S. in Business Administration from Colorado 
Technical University and an M.B.A. from Fitchburg State University. 
 
   ### 
 
   About T-knife Therapeutics 
 
   T-knife is a next-generation T-cell receptor company developing a 
pipeline of innovative therapeutics for the benefit of solid tumor 
patients and their families. The company leverages its proprietary 
humanized T-cell receptor (HuTCR) transgenic mouse platform to produce 
fully-human TCRs, naturally selected in-vivo for high affinity and 
specificity. T-knife is developing a pipeline of first / best-in-class 
TCR therapeutics against targets with high unmet medical need, including 
cancer testis antigens, viral antigens and commonly shared neo antigens. 
 
 
   T-knife was founded by leading T-cell and immunology experts using 
technology developed at the Max Delbruck Center for Molecular Medicine 
together with Charité University Hospital in Berlin, and is backed 
by leading investors, including RA Capital, Versant Ventures, Andera 
Partners and Boehringer Ingelheim Venture Fund. 
 
   Contact T-knife Therapeutics, Inc. 
 
   Camille Landis, CBO/CFO 
 
   Tel.: +49 30 94892432 
 
   https://www.globenewswire.com/Tracker?data=uybYtrP2OZy0r7XCw9iRwybthG0KCdaDagGiyoTlpllKdLj5w1bTDMXZN2p-DdjC03iDFl1KJvKBpBIF0vsL7KF_6DktyVEEzAOXtNjH_oKttV85SZhWSk0xHvH4PivUNhX1i-pt1V6rkrbynThUJviV2O051Hgtx07EwmUotfDRsigGFVp3Hu7-MPL11BHM0mb6ZC4mymDbyWdTRA6_RAUvDuGEfvhpS9pdtkF1Tgw= 
info@t-knife.com 
 
   Media Inquiries 
 
   akampion 
 
   Dr. Ludger Wess / Ines-Regina Buth 
 
   Managing Partners 
 
   info@akampion.com 
 
   Tel. +49 40 88 16 59 64 
 
   Tel. +49 30 23 63 27 68 
 
 
 
 

(END) Dow Jones Newswires

April 07, 2021 06:00 ET (10:00 GMT)

Latest news "Companies"
05:59pSCISPARC : Announces Completion of Corporate Rebranding and Launch of New Website (Form 6-K)
PU
05:59pCORENERGY INFRASTRUCTURE TRUST : Schedules Results Release for Second Quarter 2021 (Form 8-K)
PU
05:59pRYERSON : Record results, significant leverage reductions ongoing, legacy liability de-risking continuing, dividend and share repurchase plans established (Form 8-K)
PU
05:59pNU SKIN ENTERPRISES : REPORTS 42 PERCENT EPS GROWTH AND 15 PERCENT REVENUE GROWTH IN THE SECOND QUARTER (Form 8-K)
PU
05:59pNORTHWEST PIPE : Announces Second Quarter 2021 Financial Results (Form 8-K)
PU
05:59pATMOS ENERGY : Reports Earnings for Fiscal 2021 Third Quarter; Affirms Fiscal 2021 Guidance (Form 8-K)
PU
05:59pDXC TECHNOLOGY : Reports First Quarter Fiscal Year 2022 Results (Form 8-K)
PU
05:59pSOUTH JERSEY INDUSTRIES : SJI Reports Second Quarter 2021 Results Reaffirms Guidance (Form 8-K)
PU
05:59pCRYO CELL INTERNATIONAL : Employment Agreement with Oleg Mikulinsky (Form 8-K)
PU
05:59pEOG RESOURCES : Consolidated Financial Statements (Form 8-K)
PU
Latest news "Companies"